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Oseltamivir phosphate (OP) is used to treat influenza virus infections. However, its use may result in central nervous system
(CNS) adverse effects. In Japan, OP is used with Kampo formulations to improve clinical effectiveness. We evaluated the potential
for using Kampo formulations to reduce CNS adverse effects by quantifying the CNS distribution of oseltamivir and its active
metabolite oseltamivir carboxylate (OC) when administered with maoto and kakkonto. We administered lipopolysaccharide
(LPS) by intraperitoneal injection to C57BL/6 mice to reduce blood-brain barrier function. Saline, maoto, and kakkonto were
administered orally at the same time as LPS. OP was orally administered 4 hours after the last LPS injection and the migration of
oseltamivir and OC was examined. Additionally, we examined the brain distribution of OC following intravenous administration.
Changes in OC concentrations in the brain suggest that, in comparison to LPS-treated control mice, both Kampo formulations
increased plasma levels of OC, thereby enhancing its therapeutic effect. Additionally, our findings suggest kakkonto may not only
improve the therapeutic effect of oseltamivir but also reduce the risk of CNS-based adverse effects. Considering these findings, it
should be noted that administration of kakkonto during periods of inflammation has led to increased OAT3 expression.
1. Introduction
Oseltamivir phosphate (OP) elicits antiviral effects by selec-
tively inhibiting the neuraminidase in influenza virusesA and
B, making it an effective agent for prevention and treatment
of influenza infections. However, in 2012, Hoffman et al.
reported a significant incidence of abnormal behavior and
delirium induced by Tamiflu (odds ratios 29.35 and 13.50,
resp.), based on the data collected in the Food and Drug
Administration (FDA)Adverse Event Reporting System from
1999 to 2011 [1]. This study raised awareness of the adverse
neuropsychiatric effects that may accompany the use of this
anti-influenza agent. Based on the observation of a neuronal
excitation effect following application of oseltamivir and its
active metabolite oseltamivir carboxylate (OC) to juvenile rat
hippocampal slices in vitro, Usami et al. reported that OP and
OC may be involved in the induction of abnormal behavior
[2].
Infections with the influenza virus are inflammatory
diseases. Cytokines, such as tumor necrosis factor-alpha,
interleukin-1 (IL-1), and IL-6, are secreted into serum and
cerebrospinal fluid, with the increases in circulating levels of
these cytokines resulting in attenuated blood-brain barrier
(BBB) function [3, 4]. Reduced effectiveness of the BBB,
which regulates the cerebral penetration of drugs, may
increase the risk of adverse drug reactions, particularly
in regard to drug-induced central nervous system (CNS)
adverse effects, such as drowsiness, dizziness, and halluci-
nations [5]. In order to investigate these phenomena, brain
distribution of OP and OC has been analyzed in juvenile rats,
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inwhich BBB function is underdeveloped [6, 7]. Additionally,
animalmodels of inflammation have been used to analyze the
distribution of drugs into the CNS. A number of approaches
to creating thesemodels of inflammation have been reported,
including the induction of systemic inflammation through
intraperitoneal (i.p.) administration of lipopolysaccharide
(LPS) and the induction of local inflammation through
intraplantar administration of Freund’s complete adjuvant
or carrageenan [8]. Systemic inflammation induced by LPS
administration is reported to be pathologically similar to
influenza-associated encephalopathy [4]. In our previous
study, we assessed BBB integrity in mice with LPS-induced
inflammation using extravasation of Evans blue (EB) dye as
an indicator of BBB permeability. In addition to observed
reduction in BBB function, we observed that oral adminis-
tration of OP to these mice markedly increased the cerebral
penetration of oseltamivir and OC [9].
The focus of integrative medicine is increasingly becom-
ing the attainment of therapeutic effects through an organic
fusion of the modern Western medicine, complementary
therapies (such as biologic therapy, energy medicine, mas-
sage, and psychosomatic therapy), and alternative medicine
approaches (such as traditional Chinese medicine and
Ayurveda) [10]. In Japan, Kampo medicines, based on the
traditional Chinese herbal medicine, is commonly used in a
clinical setting. The Kampo formulation maoto is approved
by the Ministry of Health, Labour, and Welfare as an insur-
ance-covered treatment for influenza virus infections. OP
is sometimes used concomitantly with maoto to achieve
clinical effects [11, 12]. Maoto comprises four crude drug
components: apricot kernel, ephedra herb, cinnamon bark,
and Glycyrrhiza. In vitro studies have shown the ability of
ephedra herb to inhibit the influenza virus uncoating [13], as
well as the potential of cinnamon bark to inhibit membrane
protein synthesis [14]. Additionally, the administration of
maoto in a clinical setting was reported to achieve a general
improvement of the influenza virus-associated condition and
an antipyretic effect with effectiveness nearly identical to that
of OP [12]. Furthermore, in comparison to OP monotherapy,
concomitant treatment with maoto and OP is reported to
effectively shorten the overall duration of fever and improve
the general condition in terms of headaches andmuscle pain,
among other symptoms [11]. Kakkonto, a Kampo medicine
currently not approved as an insurance-covered treatment,
has been proposed for use as an adjunct to the treatment
of influenza virus infections with OP, on the basis of the
findings of an animal study [15] and its demonstration of
effects similar to those reported with maoto in a clinical
setting. Kakkonto comprises seven crude drug components:
puerariae root, ephedra herb, cinnamon bark, peony root,
ginger, jujube, and Glycyrrhiza. Among these components
of kakkonto formulation, ephedra herb, cinnamon bark, and
Glycyrrhiza are also present in maoto. In a study using mice
infected with the influenza virus, kakkonto increased IL-12
production in bronchoalveolar lavage fluid in the initial stage
of infection, inhibited body weight reduction, prolonged
survival periods, and reduced the mortality rate [15].
Since adverse drug reactions (i.e., neuropsychiatric
adverse effects) observed following OP administration are
considered to result from the migration of oseltamivir or
OC to the CNS, careful consideration must be given to the
potential effects of the concomitant use ofmaoto or kakkonto
on the distribution of oseltamivir and OC to the brain. Since
no studies have directly evaluated this question thus far, we
investigated the cerebral migration of oseltamivir and OC,
which are involved in the onset of CNS adverse effects, when
maoto or kakkonto is administered concomitantly with OP.
Based on our findings, we report that inflammation-induced
increase in brain penetration of OC was attenuated by the
administration of kakkonto.
2. Materials and Methods
2.1. Drugs and Chemicals. OP and OC were purchased from
Sequoia Research Products Ltd. (Pangbourne, UK) andMed-
Chemexpress Co., Ltd. (Monmouth Junction, NJ, USA),
respectively. Maoto (lot: F47711, J04981) and kakkonto
(lot: F25972, J26252) extract granules were purchased from
Tsumura Co., Ltd. (Tokyo, Japan). EB and LPS (derived from
the Salmonella enteric serotype Typhimurium) were obtained
from Sigma Chemical Co., Ltd. (St. Louis, MO, USA).
The rabbit anti-𝛽-actin polyclonal antibody (43 kDa), rat
anti-MRP4 monoclonal antibody (150 kDa), and horseradish
peroxidase- (HRP-) conjugated goat anti-rat immunoglob-
ulin (IgG) were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). The rabbit anti-OAT3 poly-
clonal antibody (59 kDa) was purchased from Biorbyt Ltd.
(Cambridge, UK). HRP-conjugated goat anti-rabbit IgG was
purchased from Enzo Life Sciences Inc. (Farmingdale, NY,
USA). All other chemicals and solvents were of reagent or
high-performance liquid chromatography (HPLC) grade and
were used without further purification.
2.2. Animals. Male C57BL/6mice (8±1weeks old) were pur-
chased from Sankyo Labo Service Corporation, Inc. (Tokyo,
Japan). Animals were reared under normal environmental
conditions; lightingwasmaintained on a 12 h light-dark cycle,
with ambient temperature maintained at 25±2∘C. All animal
experiments were approved by the Institutional Animal Care
and Use Committee of Josai University (approval number:
H24011-2012/04/04).
2.3. Quantitative Quality Analysis of Two Kampo Formula-
tions. Amounts of glycyrrhizic acid (GA), paeoniflorin (PA),
and amygdalin (AM) in the formulations were measured
as characteristic marker constituent compounds for quality
control. GA (for Crude Drugs Determination), PA (for the
Japanese Pharmacopoeia CrudeDrugs Test), andAM (for the
Japanese Pharmacopoeia Crude Drugs Test) were purchased
as reference standards from Wako Pure Chemical Industries
(Osaka, Japan). Samples of approximately 10mg of maoto or
kakkonto were measured in brown glass vials and 2mL of
80% methanol and 1mL of internal standard solution were
added. Following 10min of ultrasound irradiation, 10min
of shaking, and another 10min of ultrasound irradiation,
the solution was filtered through 0.45 𝜇m membrane filter
(PTFE, Advantec, Tokyo, Japan). The amounts of each com-
pound in the extract were measured using HPLC according
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Table 1: The measurement conditions of maker compound for quality control in kakkonto and maoto formulations.
Maker compound
for QC Column
Column
temperature (∘C) Mobile phase
Flow rate
(mL/min)
Wavelength
(nm)
Internal standard
solution (final
concentration)
GA
TSK-gel
ODS-80TM
(4.6 × 250mm)
40
200 𝜇L/L phosphoric
acid : acetonitrile (66 : 34) 1.5 254
30 𝜇g/mL amyl
4-hydroxybenzoate
PA
Deionized
water : acetonitrile : phosphoric
acid (850 : 150 : 1)
1.2 232 30 𝜇g/mL methyl4-hydroxybenzoate
AM 50mM potassium dihydrogenphosphate :methanol (5 : 1) 1.2 210
3 𝜇g/mL methyl
4-hydroxybenzoate
Time (h) 0 6 2824
LPS
Kakkonto/
maoto
LPS LPS
Drug
Kakkonto/
maoto
Kakkonto/
maoto
Figure 1: Experimental protocol for the animal study. Closed
and open arrows indicate the intraperitoneal (i.p.) injections of
lipopolysaccharide (LPS) and oral administration of Kampo formu-
lations. Striped arrow indicates the administration of Evans blue
(EB) dye or oseltamivir phosphate (OP). The concentrations of EB
were determined 120min after the intravenous injection. The con-
centrations of oseltamivir and oseltamivir carboxylate (OC) were
determined at 5, 60, and 120min following OP administration.
to the peak height method. As shown in Table 1, the measure-
ment conditions used were in accordance with the Japanese
Pharmacopoeia, 16th Edition [16], and the method described
by Honma et al. [17].
2.4. Animal Treatment for Induction of Inflammation. The
experimental protocol of this study is schematically depicted
in Figure 1. LPS (3mg/kg in 0.2mL saline/time) was admin-
istered by i.p. injections at 0, 6, and 24 h. Mice were orally
administered maoto (Mao group) or kakkonto (Kak group),
with both Kampo medications administered at 125mg/kg in
0.1mL saline at the time of LPS injections.The dose used was
previously shown to be clinically relevant, corresponding to
a human dose of 7.5 g/day for a 60 kg person. Saline (0.1mL)
was orally administered at the same intervals to the control
animals (Con group).
2.5. Measurement of Plasma and Cerebral Concentrations of
EB after Intravenous (i.v.) Administration. The integrity of
BBB was evaluated by measuring the amount of EB extracted
from brain tissue using our previously reported methods
[9]. Briefly, 2% EB solution (4mL/kg in saline) was injected
via tail vein 4 h after the third injection of LPS. Mice were
anesthetized with pentobarbital (100mg/kg i.p.) and a blood
sample was collected from the jugular vein. The thorax
was opened and the right atrium was dissected out. Mice
were perfused with 5 units/mL of heparinized saline (37∘C)
through the left ventricle until colorless perfusion fluid was
obtained. After decapitation, the brain was rapidly excised
and rinsed with ice-cold phosphate buffered saline (PBS, pH
7.4).
For quantitative determination of EB concentration,
brain tissues were homogenized in 3.5mL 50% trichloro-
acetic acid (TCA)/g tissue using a glass/Potter-Elvehjem
tissue grinder (200 rpm, 2min) with polytetrafluoroethylene
(PTFE) in ice bath and centrifuged at 4∘C (10,000×g, 15min).
The absorbance of supernatant wasmeasured at 610 nmusing
a UV-2400 PC spectrophotometer (Shimadzu Corp., Kyoto,
Japan). Blood samples were centrifuged at 4∘C (2,000×g,
15min) to obtain plasma. A sample of plasma (40 𝜇L) was
mixed with the same volume of TCA and centrifuged at
4∘C (12,000×g, 5min). The absorbance of supernatant was
measured at 610 nm.
2.6. Measurement of Plasma and Cerebral Concentrations of
Oseltamivir and OC after Oral Administration of OP. OP
(300mg/kg in 0.2mL saline) was orally administered 4 h
after the third injection of LPS. Mice were anesthetized with
pentobarbital and a blood sample was collected from the
jugular vein at 5, 60, and 120min after OP administration.
The thorax was opened, and heparinized saline was perfused
through the left ventricle until colorless perfusion fluid was
obtained. The brain tissue of mice was rapidly removed after
the decapitation and rinsed in ice-cold PBS. Three to 9 mice
were used at each sampling time point in each group.
Oseltamivir and OC levels in plasma and brain tissues
were quantified by HPLC, as described in our previous
study [9]. Blood samples collected from the jugular vein
were centrifuged to obtain plasma at 4∘C (2,000×g, 15min).
Brain tissue samples were homogenized in 3.5mL PBS/g
tissue and centrifuged at 4∘C (12,000×g, 10min). Oseltamivir
and OC were extracted from the resulting supernatant by
solid-phase extraction (SPE) using Oasis MCX extraction
cartridges (1 cc/30mg, Waters, Milford, MA, USA) condi-
tioned with 1mL of methanol followed by 1mL water. The
supernatant sample (1mL) was drawn through the cartridge
and the cartridge was washed with 1mL of 2% formic
acid/water, followed by methanol and 0.005% ammonium
hydroxide/methanol. The analytes were eluted with 3mL
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of 5% ammonium hydroxide/methanol and evaporated to
dryness under nitrogen at 40∘C. The dried extracts were
stored at −45∘C until HPLC analysis.
The HPLC system consisted of a pump (LC-10ADvp,
Shimadzu Corp., Kyoto, Japan), degasser (DGU-12A, Shi-
madzu Corp.), column (Zorbax SB-CN 5 𝜇m particle size,
4.6× 250mm,Agilent Technologies, CA, USA), column oven
(CTO-10A, Shimadzu Corp.), and UV absorbance detector
(SPD-10AV, Shimadzu Corp.). A mobile phase consisting of
acetonitrile : 10mM potassium dihydrogen phosphate buffer
(pH 3.0) = 1 : 9 (v : v) was used for the elution at the flow rate
of 1.5mL/min. The column temperature was 50∘C and the
detector was operated at absorbance wavelength of 215 nm.
The dried extract was reconstituted in 200 𝜇L of PBS and
40 𝜇L of the solution was injected onto the HPLC system.
2.7. Measurement of Carboxylesterase (CES) Activity. Liver
microsomal fractions prepared from mice of Con, Mao, or
Kak group were used as sources of the CES. Microsomal
fractions were prepared as described previously [18].
For isolation ofmicrosomal fractions,micewere perfused
with 1.15% potassium chloride solution through the left
ventricle and the liver was harvested 4 h after the third
i.p. injection of LPS. The dissected liver tissue was washed
in ice-cold PBS and homogenized with a 3 × volume of
ice-cold PBS. The liver tissue homogenate was centrifuged
at 4∘C (10,000×g, 20min). The isolated supernatant was
subsequently centrifuged to achieve complete sedimentation
of the microsomes (4∘C, 105,000×g, 60min). The pellet was
washed by resuspension in 3mL of homogenization solu-
tion and then resedimented at 105,000×g for 60min. Total
protein concentration in the microsomes was determined
using a bicinchoninic acid (BCA) protein assay kit (Pierce,
Rockford, IL, USA). The conversion of oseltamivir to OC
was quantified by measuring OC concentration at 37∘C in
an incubationmixture containing the microsomal fraction in
PBS (1mg/mL) and 100 𝜇M oseltamivir over 60min.
2.8. Measurement of Biochemical Parameters. Measurement
of blood biochemistry parameters was performed using a
VetScan VS1 Chemistry Analyzer (Abaxis, Inc., Union city,
CA, USA). Mice were anesthetized and a 0.2mL sample of
blood was collected from the jugular vein with a syringe
containing lithium heparin. The samples of whole blood
(0.1mL) were transferred to the rotor and the analysis was
performed according to manufacturer’s instructions. Alka-
line phosphatase activity (ALP), alanine aminotransferase
activity (ALT), amylase activity (AMY), creatinine levels
(CRE), blood urea nitrogen levels (BUN), total protein
concentration (TP), albumin concentration (ALB), total
bilirubin concentration (TIBIL), sodium concentration (Na),
potassium concentration (K), calcium concentration (Ca),
inorganic phosphate concentration (PHOS), and glucose
concentration (GLU) were measured.
2.9. Measurement of Plasma and Cerebral Concentrations of
OC after i.v. Administration. OC (20mg/kg in 0.1mL saline)
was injected via tail vein 4 h after the third injection of
LPS. Blood samples were withdrawn from the jugular vein
at predetermined times over 120min. Brain and plasma
OC concentrations were measured by a slight modification
of the HPLC methods described in Section 2.6 [9, 19].
Briefly, collected plasma (70𝜇L) was mixed with 910𝜇L of
0.1M hydrochloride acid and 70 𝜇L of the internal standard
solution (15𝜇g/mLpipamperone dihydrochloride). Collected
brain tissues were mixed with 4.0mL of 0.1M hydrochloride
acid/g tissue and homogenized in ice bath. Brain tissue
homogenates were centrifuged at 4∘C (12,000×g, 10min).
The resulting supernatant (900𝜇L) was mixed with 145𝜇L of
0.1M hydrochloric acid and 55 𝜇L of the internal standard
solution (20𝜇g/mL pipamperone dihydrochloride). Result-
ing mixture was subjected to SPE using Oasis MCX and the
analytes were evaporated to dryness under nitrogen. Dried
extracts were stored at −45∘C until HPLC analysis.
HPLC system for measurement of OC levels consisted
of a Mightysil RP-18 GP column (3 𝜇m particle size, 2.0 ×
150mm, Kanto Chemical, Tokyo, Japan) and a guard col-
umn (Mightysil RP-18 GP 5-2.0, 3 𝜇m particle size, Kanto
Chemical). A mobile phase consisting of acetonitrile : 10mM
potassium dihydrogen phosphate buffer (pH 3.0) = 1 : 9 (v : v)
was used for the elution, at a flow rate of 2.0mL/min. The
column temperature was 40∘C and the UV detector was
operated at absorbance wavelength of 215 nm. The dried
extract was reconstituted with 200𝜇L of eluent and an aliquot
(40 𝜇L) of the solution was injected onto the HPLC system.
2.10. Western Blot Analysis. Obtained brain tissue was
homogenized with a 5 × volume of homogenate buffer (0.1M
Tris-HCl buffer, pH 8.0) containing 1mM phenylmethylsul-
fonyl fluoride, 1mM dithiothreitol, 20𝜇g/mL aprotinin, leu-
peptin, and pepstatin in ice bath. Brain tissue homogenates
were subsequently centrifuged at 4∘C (6,500×g, 15min).
Isolated supernatants were subsequently centrifuged at
140,000×g for 30min at 4∘C. The pellet was dissolved in
homogenate buffer containing 1% NP-40.
The protein concentration in the solutionwas determined
using the BCA protein assay kit. Sodium dodecyl sulfate
(SDS, 1%) was added to each sample and heated to 95∘C.
Protein solution (25 𝜇g per lane) was loaded onto a 7.5% SDS-
polyacrylamide gel and subjected to electrophoresis. The
separated proteins were transferred onto a nitrocellulose
membrane.Themembrane was blocked with PBS containing
0.1% Tween 20 (PBST) and 5% skimmilk and then incubated
at room temperature for 1 h. After washing 3 times with
PBST (5min for each wash), membranes were incubated at
4∘C overnight with primary antibodies: anti-OAT3 antibody
(diluted 1 : 500 with PBST), anti-MRP4 antibody (diluted
1 : 100 with PBST), or anti-𝛽-actin antibody (diluted 1 : 1,000
with PBST). After washing 3 times with PBST, membranes
were incubated at room temperature for 1 h with secondary
antibodies (HRP-conjugated goat anti-IgG; 1 : 5,000). The
membranes were washed 4 times with PBST and the bands
were detected using the SuperSignal West Dura Extended
Dura Trial Kit (Takara Bio. Inc., Shiga, Japan). The chemi-
luminescence was detected using an LAS-1000 instrument
(Fujifilm, Tokyo, Japan). Pixel density of transporter proteins
was determined using the Image J software program.
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Table 2: Amounts of marker constituent compounds in kakkonto and maoto extract formulations.
Kampo formulation Maker compound for QC Amount listed in JP16 (in 7.5 g) Amount per lot (in 7.5 g)
H44002 J26252
Kakkonto Glycyrrhizic acid 19–57mg 27.7 ± 0.2mg 25.8 ± 0.36mg
Paeoniflorin 14–56mg 27.7 ± 0.4mg 30.4 ± 0.63mg
F47711 J04981
Maoto Glycyrrhizic acid 14–42mg 31.1 ± 0.46mg 31.1 ± 0.25mg
Amygdalin 48–192mg 102.7 ± 2.87mg 90.4 ± 3.66mg
Data represent the mean ± S.D. (𝑛 = 3).
2.11. Statistical Analysis. All data are presented as means ±
SD. Significance between group means was determined by
the Tukey-Kramer test. 𝑃 < 0.05 was considered to be
significant. All analyses were conducted using software from
the R Project for Statistical Computing (R version 2. 15.2).
3. Results
3.1. Amounts of Marker Constituent Compounds in Kampo
Formulations. The amounts of marker constituent com-
pounds in kakkonto and maoto formulations used in the
present study were within the range listed in the Japanese
Pharmacopoeia, 16th Edition (Table 2).
3.2. Effect of Maoto or Kakkonto Administration on BBB Integ-
rity. Thebrain-to-plasma ratio (BPR) of EB, used as an index
of BBB disruption, was measured in each treatment group,
with the results presented in Figure 2. BPR in the Mao
and Kak groups was 0.50- and 0.48-fold lower than those
calculated in the Con group, respectively.
3.3. Plasma and Brain Concentrations of Oseltamivir and OC
afterOral Administration of OP in CombinationwithMaoto or
Kakkonto. OP solution was orally administered to the mice
in Con, Mao, and Kak groups. Figures 3(a) and 3(b) show the
plasma concentrations of oseltamivir and OC following oral
administration of OP. Plasma concentration of oseltamivir
was increased in the Mao and Kak treatment groups during
the experimental period compared to the Con group, with
significant differences observed between the Kak and Mao
groups. The area under the concentration time curve from
0 to 120min following dose (AUC
0–120) of the Mao group
was 1.92 times higher than that of the Con group, whereas
the AUCplasma-oseltamivir, 0–120 of Kak group was 2.60 times
higher than that of the Con group. While no significant
difference in plasmaOC levelswas observed between theMao
and Con groups, levels in the Kak group were significantly
higher at 5 and 120min after administration (Figure 3(b)).
AUCplasma-OC, 0–120 of Mao and Kak groups was 1.12 and 1.57
times higher, respectively, than that of Con group.
Figures 4(a) and 4(b) show the cerebral concentrations
of oseltamivir and OC following oral administration of OP.
Cerebral oseltamivir levels were higher in the Kak group
than in the Con group at 60 and 120min after administra-
tion. While no significant difference in cerebral oseltamivir
concentrations was noted during the experimental period
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Figure 2: Effect ofmaoto or kakkonto administration on BBB integ-
rity in mice with lipopolysaccharide- (LPS-) induced inflammation.
Brain and plasma concentrations of Evans blue (EB) dye were deter-
mined 120min after intravenous injection of EB. Data represent the
means ± S.D. of 4–7 mice. ∗𝑃 < 0.05, Tukey-Kramer test.
in the Mao group, the levels were observed to be slightly
higher than those measured in the Con group (Figure 4(a)).
AUCbrain-oseltamivir, 0–120 values in Mao and Kak groups were
1.51 and 2.52 times higher, respectively, than the mean
AUCbrain-oseltamivir, 0–120measured in the Con group. BrainOC
levels in the Kak group were lower than those measured
in the Con group throughout the experimental period,
reaching significant difference at 60min after administration.
AUCbrain-OC, 0–120 values in Mao group were 1.18 times higher
than those in the Con group, whereas those measured in the
Kak group were 0.37 times lower than those measured in
control mice.
The mean BPR was calculated as the ratio between mean
AUCbrain and mean AUCplasma and used as an index of the
penetration of oseltamivir and OC into the brain. BPR of OC
in the Kak group was significantly lower than that calculated
in the Con group (Table 3). The cerebral migration of OC,
which was increased by LPS injection, was inhibited by
concomitant administration of kakkonto.
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Figure 3: Plasma concentrations versus time profiles of (a) oseltamivir and (b) oseltamivir carboxylate (OC) after the administration of
oseltamivir phosphate (OP) to mice with LPS-induced inflammation. Mice were pretreated with three i.p. injections of LPS (3mg/kg) with
concurrent oral administration of (e) saline (control), (◻) maoto, or (△) kakkonto. A single oral dose of OP (300mg/kg) was administered
to mice 120min after the third injection of LPS. Horizontal bar represents the mean values. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, Tukey-Kramer test.
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Figure 4: Brain concentrations versus time profiles of (a) oseltamivir and (b) oseltamivir carboxylate (OC) after the administration of
oseltamivir phosphate (OP) to mice with lipopolysaccharide- (LPS-) induced inflammation. Mice were pretreated with three intraperitoneal
(i.p.) injections of LPS (3mg/kg) with concurrent oral administration of (e) saline (control), (◻) maoto, or (△) kakkonto. A single oral dose
of OP (300mg/kg) was administered to mice 120min after the third injection of LPS. Horizontal bar represents the mean values. ∗𝑃 < 0.05
and ∗∗𝑃 < 0.01 (versus control), Tukey-Kramer test.
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Table 3: The AUC
0–120 and the mean brain-to-plasma ratio (BPR) of oseltamivir and oseltamivir carboxylate (OC) following oral admin-
istration of oseltamivir phosphate (OP) to mice with lipopolysaccharide- (LPS-) induced inflammation.
Group
AUC BPR
Plasma (min⋅𝜇g/mL) Brain (min⋅𝜇g/g brain) (𝜇L/g brain)
Oseltamivir OC Oseltamivir OC Oseltamivir OC
Con 1949.86 762.01 79.35 16.06 40.70 21.08
Mao 3749.85 856.89 119.92 18.95 31.98 22.12
Kak 5066.10 1199.90 200.21 5.98 39.52 4.98
Con: control; Kak: kakkonto-treated; Mao: maoto-treated.
Table 4: Blood biochemistry parameters in mice with lipopolysaccharide- (LPS-) induced inflammation.
Parameter (units) Con Mao Kak
ALP U/L 51.4 ± 47.96 25.5 ± 9.57 33.6 ± 7.57
ALT U/L 71.2 ± 33.81 61.5 ± 14.29 69.6 ± 8.08
AMY U/L 1058.2 ± 240.48 796.2 ± 63.24 949.8 ± 225.76
CRE mg/dL 0.5 ± 0.24 <0.2#,∗ <0.2#,∗
BUN mg/dL 75.8 ± 51.91 70.7 ± 24.71 59.4 ± 9.42
TP g/dL 5.3 ± 0.23 5.0 ± 0.33 5.0 ± 0.13
ALB g/dL 2.7 ± 0.17 2.7 ± 0.15 2.6 ± 0.14
TBIL mg/dL 0.3 ± 0.04 0.2 ± 0.09 0.2 ± 0.05
Na+ mmol/L 145.8 ± 6.14 141.3 ± 3.67 139.4 ± 2.97
K+ mmol/L 6.9 ± 1.10 7.2 ± 1.39 7.3 ± 1.07
Ca++ mg/dL 9.4 ± 0.22 9.1 ± 0.45 8.9 ± 0.37
PHOS mg/dL 10.2 ± 3.13 9.4 ± 1.73 10.2 ± 0.82
GLU mg/dL 33.6 ± 19.81 69.3 ± 10.56∗ 65.4 ± 6.99∗
Data represent the mean ± S.D. (𝑛 = 5-6).
∗
𝑃 < 0.05 (versus control).
#Below the limit of quantitation.
3.4. Evaluation of Esterase Enzymatic Activities. The conver-
sion rates of oseltamivir toOC in livermicrosomes frommice
inMao or Kak group were not significantly different from the
conversion rate measured in the Con group (Figure 5).
3.5. Change in the Biochemical Markers byMaoto or Kakkonto
Administration. The relevant biochemical parameters are
summarized in Table 4. CRE concentration was decreased
to the lower limit of quantification by the concomitant
administration of kakkonto or maoto in LPS-treated mice.
GLU concentration was significantly higher in Mao and Kak
groups than in the Con group. No significant difference was
observed in other biochemical parameters.
3.6. Plasma and Brain Concentrations of OC after Intra-
venous Administration of OC in Combination with Maoto or
Kakkonto. Figure 6 shows the plasma (panel (a)) and cerebral
(panel (b)) OC concentrations after intravenous adminis-
tration of OC. In the kakkonto-treated mice, plasma OC
levels were lower than those measured in LPS-treated control
animals (Con group). No significant difference was observed
between the Mao and Con groups in plasma OC levels.
Moreover, cerebral OC levels in the mice of Kak group were
lower than those of the Con group. While cerebral OC levels
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Figure 5: Effect of maoto or kakkonto Kampo formulations on the
rate of oseltamivir conversion to the active carboxylate metabolite
(OC) in mice with LPS-induced inflammation. Liver microsomal
fractions prepared from mice administered three i.p. injections of
3.0mg/kg LPS were used as a source of carboxylesterase. Data
represent the means ± S.D. of 3–5 mice.
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Figure 6: Plasma (a) and brain (b) concentrations versus time profiles of oseltamivir carboxylate (OC) after the administration of OC tomice
with lipopolysaccharide- (LPS-) induced inflammation.Mice were pretreated with three intraperitoneal (i.p.) injections of LPS (3mg/kg) with
concurrent oral administration of (e) saline, (◻) maoto, or (△) kakkonto. Control animals were administered saline vehicle without LPS (I).
A single intravenous dose of OC (20mg/kg) was administered to mice 120min after the third injection of LPS.
in theMao group were lower than thosemeasured in the Con
group, they were not different from those measured in the
Kak group. Plasma and cerebral OC levels in the LPS-injected
mice were elevated compared to the corresponding levels in
the mice that were not treated with LPS. Coadministration
of kakkonto attenuated this increase in OC concentration
and reduced the variation in OC levels. The difference in
OC levels between Kak and Con groups was analyzed using
the 𝐹-test at each time point, with the difference in the
mean value between Kak and noninflammatory (without
LPS administration) groups analyzed using the unpaired
𝑡-test at each time point. Comparing the Kak and Con
groups, significant differences were observed in the brain OC
concentrations throughout the experimental period and in
the plasma at 120min after administration (plasma: 120min;
𝑃 = 0.044, brain: 5min; 𝑃 = 0.023, 60min; 𝑃 = 0.036,
120min; 𝑃 = 0.008). Additionally, comparing the mean OC
levels in Kak group with those measured in mice who did
not receive LPS treatment, significant differences in cerebral
concentrations were only found 120min after administration,
while no significant differences were observed in plasma
concentration (plasma: 5min; 𝑃 = 0.106, 60min; 𝑃 = 0.204,
120min; 𝑃 = 0.304, brain: 5min; 𝑃 = 0.638, 60min;
𝑃 = 0.853, 120min; 𝑃 = 0.005). These results suggest that
kakkonto suppresses the increased brain penetration of OC
in the presence of inflammation.
3.7. Effect ofMaoto or Kakkonto on the Expression of OAT3 and
MRP4 in the Brain. The results of Western blotting analysis
demonstrated that brain OAT3 expression in the Kak group
was 1.28 times higher than that in the Con group, with only
Kak group showing an increase. While OAT3 expression was
observed to be significantly increased following kakkonto
administration, no changes in MRP4 expression were noted
between the groups (Figure 7).
4. Discussion
In children with influenza virus infections, the use of OP
is indicated to be associated with abnormal behavior. The
concomitant use of OP and maoto in patients infected
with the influenza virus was reported to be effective in
significantly shortening fever duration, as well as achieving
early improvement of physical symptoms such as fatigue,
dizziness, and loss of appetite [11, 12]. In addition, kakkonto,
which has a composition of crude drugs similar to that
of maoto, has demonstrated in the results of a basic study
[15] and in clinical settings the potential to achieve results
similar to those of maoto. Despite the potential benefits of
concomitant administration of kakkonto with OP, we found
no studies evaluating the cerebral penetration of oseltamivir
or OC with the use of these Kampo formulations.
The migration of substances from the blood to the
cerebral parenchyma is regulated by the BBB. BBB is com-
posed of tight junctions between the endothelial cells of
brain microvasculature, astrocytes, and pericytes. Addition-
ally, efflux transporters affect the penetration of substrates
through the BBB. The substance permeation mechanism of
the BBB, which is based on passive diffusion, is divided into
the paracellular and the transcellular pathways [20]. Paracel-
lular pathway is involved in the migration of water-soluble
low-molecular weight (MW) compounds. However, because
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Figure 7: Effects of kakkonto and maoto on the expression of OAT3 and MRP4 proteins in the brain. (a) Representative images of the
expression of OAT3 and MRP4 proteins in the brain and (b) OAT3 and MRP4 expression levels in the brain, quantified by Western blot
analysis. Data represent the mean ± S.D. of 6 mice. ∗𝑃 < 0.05.
of the presence of tight junctions, almost no substance
penetrates the BBB by this pathway. Conversely, transcellular
pathway is involved in the penetration of lipid-soluble low-
MWcompounds into the brain.The penetration through this
pathway, however, is restricted to compounds with MW of
<500 or a log𝑃 near 2. One method of assessing the integrity
of BBB is to inject EB i.v. and subsequently measure the
amount of EB that entered into the cerebral parenchyma. EB
is a water-soluble dye with a MW of 960.8 that shows nearly
complete binding to plasma albumin (MW of approximately
66,000). Therefore, it normally does not penetrate the BBB
[21]. However, when BBB function is attenuated with cell
injury as an inflammation, the paracellular pathway opens,
and EB bound to albumin in the blood enters the cerebral
parenchyma. Using the BPR of EB as an indicator, we
have previously reported that BBB function is attenuated
in mouse models of LPS-induced inflammation [9]. In the
present study, oral administration of kakkonto and maoto
formulations along with i.p. injection of LPS resulted in lower
EB BPR, as compared to the BPRmeasured in animals treated
with i.p. injections of LPS alone.This result demonstrates that
the compromised integrity of the BBB caused by the LPS-
induced inflammationwas ameliorated by the administration
of kakkonto and maoto. This observed improvement in BBB
integrity may reflect a restoration of the barrier function
blocking the paracellular brain penetration pathway.
Next, we evaluated the effect on brain penetration of
oseltamivir and OC following oral administration of OP in
a mouse model of inflammation. Due to their physical prop-
erties, oseltamivir (MW = 312.0, 𝑐 log𝑃 = 1.29) and its active
metabolite OC (MW= 284.4, 𝑐 log𝑃 = −0.97) do notmigrate
easily by passive diffusion from the blood to the cerebral
parenchyma [22, 23]. Additionally, oseltamivir is a substrate
for the efflux transporter P-glycoprotein (P-gp), while OC is
a substrate for the organic anion transporter (OAT) 3 and
multidrug resistance protein (MRP) 4. Since oseltamivir and
OC are excreted from the cerebral parenchyma to the blood,
they normally do not distribute to the CNS [24].
In our previous report, with oral administration of OP
in a noninflammation group (injected with saline vehicle)
and a control group (injected with LPS in saline), the plasma
concentration of oseltamivir was found to bemarkedly higher
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in the LPS-treated animals than in the noninflammation
group, whereas plasma OC concentrations were similar.
Additionally, brain concentrations of oseltamivir and OC
were markedly higher in LPS-treated mice than in the saline-
treated animals [9]. Pueraria root and peony root, crude
components of the kakkonto formulation, promote gastroin-
testinal motility and dilate peripheral arteries, respectively,
while cinnamon bark, a common crude drug component of
both kakkonto and maoto, also dilates peripheral arteries
[25]. The increase in plasma concentrations of oseltamivir in
the present study may therefore be the result of increased
absorption of oseltamivir from the intestine due to the
promotion of gastrointestinal motility. Additionally, admin-
istration of kakkonto or maoto did not yield any change
in CES activity in the liver in comparison to the control
group. Therefore, changes in plasma OC concentrations
may reflect increased plasma concentrations of the prodrug
oseltamivir. Furthermore, considering brain concentrations
of oseltamivir and OC from the perspective of the risk
of CNS adverse effects, brain concentrations of oseltamivir
in mice treated with Kampo formulations, and brain con-
centrations of OC in the maoto-treated mice demonstrated
similar patterns to those observed in blood levels. Conversely,
kakkonto-treatedmice demonstrated differences in brainOC
concentrations different from those observed in blood con-
centrations; namely, brain OC concentrations were found to
be decreased in comparison to the control group, regardless
of increased blood OC levels. Lower cerebral penetration
(indexed as lower BPR) relative to the control group was
observed only with OC levels in the kakkonto group. Overall,
these findings suggest that kakkonto and maoto differ from
each other in their effect on brainOC levels. In order to assess
in more detail the effect of kakkonto on cerebral penetration
of OC, we evaluated the changes in blood biochemistry and
assessed the effect of i.v. administration of OC.
In our serum biochemical examination, oral adminis-
tration of kakkonto or maoto decreased CRE concentration
to the lower limit of quantification, suggesting that renal
function returned to values within normal limits. Maoto and
kakkonto are commonly used to treat colds and inflammatory
diseases. Previously performed study reported an inhibition
of carrageenan-induced edema and cotton pellet-induced
granuloma formation in mice, suggesting that kakkonto and
maoto inhibit the effusion phase and the late growth phase
of the early stage of inflammation [26]. Our results may,
therefore, signify that the markedly reduced renal function
and somewhat reduced hepatic function observed in mice
with BBB hypofunction can be recovered through the anti-
inflammatory effects of kakkonto and maoto. Because OC is
a renally excreted drug, lower plasma concentrations of OC
(associated with the recovery of renal function) were noted
after administration of maoto or kakkonto when compared
with the LPS-treated Con group. Moreover, administration
of kakkonto led to increased OAT3 expression in the brain
compared to the expression inCon group,whichmay account
for the decreased brain concentrations of OC.
The results of the present study show that maoto and
kakkonto Kampo formulations increase plasma concentra-
tions of oseltamivir and OC. Maoto and kakkonto exhibit
different effects on OC distribution, with only kakkonto
reducing the brain concentrations of OC. These findings
indicate that the concomitant use of kakkonto with OP
may reinforce the anti-influenza effect and reduce the risk
of CNS adverse effects. Our results also suggest that the
concomitant use of maoto with OP may reinforce the anti-
influenza effect with no effect on the risk of CNS adverse
effects. Further studies are warranted to evaluate the potential
for applications of these two Kampo formulations as adjunct
to OP treatment of influenza infection in a clinical setting.
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